Sino Biological, a global leader in recombinant technology, has launched o XPressMAX™ cell-free protein synthesis kit, a cutting-edge solution designed to supercharge artificial intelligence (AI)-driven high-throughput screening pipelines for antibody drug discovery.
The novel kit leverages advanced cell-free protein synthesis technology to enable rapid, efficient in vitro production of target proteins and antibodies, eliminating the constraints of traditional cell-based expression systems. By seamlessly integrating with AI-powered screening platforms, the kit helps researchers accelerate the identification and optimisation of antibody candidates, reducing both development timelines and costs.
Based on an E. coli lysate and fully supplemented with essential transcription and translation components, XPressMAX enables direct protein synthesis from plasmid or PCR templates. Designed for antibody drug discovery, XPressMAX enables rapid expression and validation of VHH, scFv, Fab, and Miniprotein. Leveraging XPressMAX, Sino Biological has established a high-throughput cell-free platform that validates 2,000+ scFv/VHH molecules in three to four weeks, matching AI’s rapid iteration.
XPressMAX highlights
• Ultra-fast synthesis: synthesis completed in just three hours
• High success rate: >99%
• Supports complex disulfide bonding: native folding and bioactivity without additional enhancers.
